Bayer Makes Tentative Deal in Drug-Price Probe
WASHINGTON - In the first settlement of a state and federal investigation of drug-industry pricing practices, a US unit of Bayer AG has tentatively agreed to pay $14 million to resolve allegations that it caused Medicaid to overpay for its drugs. Bayer, which has confirmed a settlement, has not admitted wrongdoing. The settlement requires that the company report more accurate price information for all of its drugs to state and federal regulators. In addition, the company must cooperate with continuing investigation.
More than 20 drug companies are under current investigation, including Abbott Laboratories, Bristol-Myers Squibb Co., Glaxo Wellcome PLC's US unit, and SmithKline Beecham PLC. All companies have denied any wrongdoing. For more information visit www.hcfa.gov/medicaid.
Obituary: In Memory of SMART4TB and Project ACCELERATE
March 14th 2025In this remembrance of SMART4TB and Project ACCLERATE, 2 global health initiatives, Heather Stoltzfus, MPH, RN, CIC, explains what they are and why they serve as a warning of what has been lost and what more could be lost in the future.
The Art of Wise Leadership in Infection Control and Quality Management
March 14th 2025Discover how wise leadership in infection control transforms challenges into opportunities, fosters teamwork, and safeguards patient safety through emotional intelligence, strategic vision, and inspiring action.
The CDC at a Crossroads: Budget Cuts, Public Health, and the Growing Threat of Infectious Diseases
March 12th 2025Budget cuts to the CDC threaten disease surveillance, outbreak response, and public health programs, increasing risks from measles, avian flu, and future pandemics while straining health care infrastructure nationwide.
Standing Up for Science: A Rally Participant’s Perspective
March 11th 2025Infection Control Today's Editorial Advisory Board member and contributing editor, Heather Stoltzfus, MPH, RN, CIC, recently joined the Stand Up for Science rally in Washington, DC. She gives a first-person perspective on the rally and the rally-goers' strong message.
